Vice President
Celldex Therapeutics
Vice President
Celldex Therapeutics
Develops antibody-based therapies targeting inflammatory diseases
The Vice President, Clinical & Development Sciences will serve as a senior medical and scientific leader within Celldex's Clinical organization and a key partner to the Chief Medical Officer. This individual will provide strategic leadership across clinical development programs, helping shape and execute development strategies designed to advance Celldex's portfolio from proof of concept through late-stage development leading to regulatory approval, and in the post-marketing phase.
The Vice President will provide medical and scientific leadership across clinical programs, including development strategy, clinical trial design and execution, medical monitoring and patient safety, and interpretation of clinical data.. They will partner closely with other Celldex leaders on regulatory strategy and interactions, scientific communications, and engagement with the medical community.
As a senior leader within Clinical Development, this individual will work closely with Clinical Operations, Regulatory Affairs, Clinical Pharmacology and Pharmacometrics, Translational Medicine, Biostatistics, Data Management, Pharmacovigilance and Risk Management and other functions to ensure integrated development strategies and high-quality execution. They will also partner with Medical Affairs and the Commercial Team to support scientific communications and evidence generation, and to ensure alignment of clinical development strategies with the needs of the medical community and patients.
The Vice President will also play an important leadership role in building and developing the Clinical Development organization, mentoring clinical development and clinical science talent, and establishing the capabilities required to support Celldex's advancing pipeline.
Clinical Development Strategy & Leadership
Clinical Trial Strategy & Execution
Data Interpretation & Scientific Communication
Regulatory & Development Strategy
External Scientific Leadership
Organizational Leadership
Develops antibody-based therapies targeting inflammatory diseases
Celldex Therapeutics develops antibody-based therapies for inflammatory, allergic, and autoimmune diseases, focusing on mast cell biology. Its lead program barzolvolimab is a humanized monoclonal antibody that inhibits KIT, reducing mast cell activity and inflammation; its pipeline includes other antibodies designed to engage the immune system or modulate disease pathways. The company leverages partnerships and licensing in addition to developing its own therapies to create a breadth of programs in its target areas. Its goal is to deliver therapies that lessen inflammation and autoimmune activity by targeting mast cells and related signaling pathways.
Explore more opportunities at Celldex Therapeutics